| Targeting CCR5 as a component of an HIV-1 therapeutic strategy H Mohamed, T Gurrola, R Berman, M Collins, IK Sariyer, ... Frontiers in immunology 12, 816515, 2022 | 42 | 2022 |
| Immunomodulatory Effects of Non-Thermal Plasma in a Model for Latent HIV-1 Infection: Implications for an HIV-1-Specific Immunotherapy H Mohamed, R Berman, J Connors, EK Haddad, V Miller, ... Biomedicines 11 (1), 122, 2023 | 3 | 2023 |
| Computational analysis of cas proteins unlocks new potential in HIV-1 targeted gene therapy W Dampier, R Berman, MR Nonnemacher, B Wigdahl Frontiers in genome editing 5, 1248982, 2024 | 2 | 2024 |
| Altered recruitment of Sp isoforms to HIV-1 long terminal repeat between differentiated monoblastic cell lines and primary monocyte-derived macrophages JJ McAllister, S Dahiya, R Berman, M Collins, MR Nonnemacher, ... Frontiers in Virology 2, 971293, 2022 | 1 | 2022 |
| What's in a cure: designing a broad-spectrum HIV gene therapy RE Berman, W Dampier, MR Nonnemacher, B Wigdahl Current Opinion in HIV and AIDS 19 (3), 150-156, 2024 | | 2024 |
| Role of extracellular viral regulatory proteins in neuropathogenesis MR Nonnemacher, RE Berman, JM Lawrence, ME Collins, TE Gurrola, ... HIV-Associated Neurocognitive Disorders, 179-207, 2024 | | 2024 |
| PP 6.5–00205 Utilization of high-throughput assays and deep-learning for selection of CRISPR/Cas9-gRNA pairs used in an HIV-1 cure strategy R Berman, W Dampier, A Atkins, A Allen, V Pirrone, S Passic, A Ahmed, ... | | 2022 |
